Clinical Trial

AntiThrombotic Therapy to Ameliorate Clinical Complications in Community Acquired Pneumonia

Study acronym: ATTACC-CAP
Recruiting Phase 3
View on ClinicalTrials.gov →
Summary
This is an international, open-label, stratified randomized controlled trial with Bayesian adaptive stopping rules to compare the effects of therapeutic-dose heparin vs. usual care pharmacological thromboprophylaxis on outcomes in patients admitted to hospital with community acquired pneumonia (CAP).
Protocol Amendment History 11 amendments
This ClinicalTrials.gov record has been amended 11 times since 2023-04-28; most recent amendment 2026-04-16.
Status change: Not Yet Recruiting → Recruiting 2023-11-07
Trial Details
NCT Number NCT05848713
Lead Sponsor University of Manitoba
Collaborators: Canadian Institutes of Health Research (CIHR), Research Manitoba, Ozmosis Research Inc., Canadian Venous Thromboembolism Clinical Trials and Outcomes Research (CanVECTOR) Network, Canadian Critical Care Trials Group, Avanti PC, Aurora Clinical Research
Conditions Community-acquired Pneumonia
Enrollment 4,000 participants
Start Date 2023-10-10
Primary Completion 2028-03-31 (estimated)
Study Completion 2029-03-31 (estimated)
Updated on ClinicalTrials.gov 2026-04-21